Gland Pharma Ltd. (GLAND) 52 Week High Streak: Second Straight Session Near Peak
- September 30, 2026
- Posted by: Chaitanya Auti
- Category: News
Gland Pharma Ltd. 52 Week High Streak has now held for its second straight session, with the stock trading within 2% of its 52-week high again and moving across the streak by -1.28%. The latest Univest data confirms the price pattern, but it does not establish a company-specific catalyst for the repeated near-high trade. Gland Pharma Ltd. 52 Week High Streak is therefore best read as a multi-session market pattern rather than a one-day event.
As of 09 October 2026 at 11:52 AM IST, Gland Pharma Ltd. (GLAND) was trading at Rs 3,111.65, after a previous close of Rs 3,069.9, with the day open at Rs 3,067.9 and the day low at Rs 3,011.6. The market capitalisation stood at Rs 52,010.6 crore. For readers tracking Gland Pharma Ltd. Share Price, the repeated-high pattern matters because it reflects persistence near the yearly high across sessions, not just a single intraday move.
Gland Pharma Ltd. 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 3,111.65 |
| Previous Close | Rs 3,069.9 |
| Today's Move | +Rs 41.75 (+1.36%) |
| Open | Rs 3,067.9 |
| High | Rs 3,117.4 |
| Low | Rs 3,011.6 |
| Market Capitalisation | Rs 52,010.6 crore |
Gland Pharma Ltd. (GLAND) traded at Rs 3,111.65 versus the previous close of Rs 3,069.9, a rise of 1.36%. The stock opened at Rs 3,067.9, reached a high of Rs 3,117.4 and touched a low of Rs 3,011.6.
Gland Pharma Ltd. Share Price Today is higher than the previous close by Rs 41.75, or 1.36%, with the stock last traded at Rs 3,111.65. The day began at Rs 3,067.9 and traded between Rs 3,011.6 and Rs 3,117.4, placing the last traded level near the upper end of the day’s range. That keeps Gland Pharma Ltd. Share Price in the conversation around stocks at one year high today, even though the stock has not been described here as making a fresh record.
For market readers, the important point is that Gland Pharma Ltd. Share Price Today sits close to the 52-week peak for a second straight session, which makes Gland Pharma Ltd. 52 Week High Streak the more useful frame than a single-day headline. The move should also be viewed alongside the company’s market capitalisation of Rs 52,010.6 crore and the fact that the latest price action alone does not explain why Gland Pharma Ltd. Share Price has stayed near the high. That keeps Gland Pharma Ltd. Stock News focused on the pattern rather than a confirmed trigger.
What the Repeated 52-Week Highs Show
Gland Pharma Ltd. 52 Week High Streak shows that the stock has remained near its yearly high for a second straight session, with the current streak move at -1.28% across the period. In plain terms, the latest Gland Pharma Ltd. New One Year High-style interest is about continuity near the peak, not necessarily about a fresh break above it. The data confirms the repeated pattern, but it does not identify a company-specific reason for the persistence.
For readers searching Gland Pharma Ltd. Consecutive 52 Week High or Gland Pharma Ltd. Back To Back 52 Week Highs, the key distinction is that a near-high streak can continue even without a new high being printed every day. This is why the streak deserves a separate read from a one-day move. The pattern also keeps the stock in the broader set of 52 Week High Stocks and Stocks At One Year High Today, which often attract attention from market watchers following Gland Pharma Ltd. Stock Performance.
Gland Pharma Ltd. (GLAND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 52,010.6 crore |
| P/E Ratio | 44.88x |
| P/B Ratio | 4.77x |
| ROE | 10.56% |
| ROCE | 14.96% |
| EPS | Rs 68.41 |
| Book Value Per Share | Rs 644.16 |
| Dividend Yield | 0.65% |
Gland Pharma Ltd. (GLAND) fundamental metrics show P/E 44.88x, P/B 4.77x, ROE 10.56%, ROCE 14.96%. These figures provide context only and are not a buy or sell signal.
Gland Pharma Ltd. has a market capitalisation of Rs 52,010.6 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 44.88x, P/B at 4.77x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 10.56% and ROCE of 14.96%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 68.41, book value per share of Rs 644.16, dividend yield of 0.65%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 27.02x, median ROE of 11.61%, median ROCE of 13.28%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 44.88x |
| Benchmark Median P/E | 27.02x |
| Benchmark Average P/E | 39.96x |
| Benchmark P/E Range | 0x to 678.22x |
| Company P/B Ratio | 4.77x |
| Benchmark Median P/B | 2.79x |
| Company ROE | 10.56% |
| Benchmark Median ROE | 11.61% |
| Company ROCE | 14.96% |
| Benchmark Median ROCE | 13.28% |
| Company Market Capitalisation | Rs 52,010.6 crore |
| Benchmark Median Market Cap | Rs 803.77 crore |
Gland Pharma Ltd. (GLAND) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Gland Pharma Ltd. (GLAND) has a P/E ratio of 44.88x, which is above the benchmark median of 27.02x, a difference of +66.1%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Gland Pharma Ltd. (GLAND) has a ROE of 10.56%, which is below the benchmark median of 11.61%, a difference of -9.04%. Gland Pharma Ltd. (GLAND) has a ROCE of 14.96%, which is above the benchmark median of 13.28%, a difference of +12.65%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Anthem Biosciences Ltd. | ANTHEM | 49,990.57 | 85.42 | 15.72 | 21.98 | 29.62 |
| Ipca Laboratories Ltd. | IPCALAB | 49,197.05 | 37.37 | 5.77 | 15.88 | 19.41 |
| Abbott India Ltd. | ABBOTINDIA | 55,433.37 | 33.73 | 10.52 | 34.67 | 46.72 |
| Biocon Ltd. | BIOCON | 58,750.47 | 114.83 | 1.67 | 1.35 | 3.26 |
| Glaxosmithkline Pharmaceuticals Ltd. | GLAXO | 44,608.84 | 40.2 | 17.04 | 48.76 | 66.79 |
Gland Pharma Ltd. (GLAND) has a P/E ratio of 44.88x compared with the displayed peer median of 40.2x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 10.56% compares with a peer median of 21.98% across the companies shown in the table. ROCE stood at 14.96% versus the displayed peer median of 29.62%, providing a capital-efficiency comparison. Gland Pharma Ltd. (GLAND) has a market capitalisation of Rs 52,010.6 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Gland Pharma Ltd.
- Gland Pharma Ltd. 52 Week High Streak has continued for a second straight session, keeping Gland Pharma Ltd. Share Price near its yearly high.
- The latest move across the streak is -1.28%, which makes the multi-session pattern more important than a one-day headline.
- Gland Pharma Ltd. Fundamental Analysis shows a P/E of 44.88 and a P/B of 4.77, both above the industry median.
- Gland Pharma Ltd. Market Cap of Rs 52,010.6 crore places it among the larger listed names in the pharmaceuticals & drugs universe.
- Gland Pharma Ltd. Stock News remains relevant because the repeated near-high pattern is confirmed, while the reason behind it is not established.
About Gland Pharma Ltd.
Gland Pharma Ltd. operates in the healthcare sector and the pharmaceuticals & drugs industry. The company is tracked on NSE and BSE under the symbol GLAND. In market terms, Gland Pharma Ltd. Share Price has stayed in focus because the stock is trading near its 52-week high again, while the broader company profile includes a market capitalisation of Rs 52,010.6 crore, a P/E of 44.88 and a P/B of 4.77.
For readers comparing Gland Pharma Ltd. Stock Performance with other healthcare names, the key context is valuation and sector placement rather than a single-day move. The stock’s recent behaviour keeps it in the set of stocks hitting 52 week highs and stocks in news today, which can matter to market watchers who follow breakout-style moves across established listed companies.
This article is for information only and should not be read as a recommendation. It reflects the latest market snapshot and company metrics available at the time of publication.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
What does Gland Pharma Ltd. 52 Week High Streak mean?
Ans. It means Gland Pharma Ltd. has traded within 2% of its 52-week high for a second straight session. The pattern shows repeated proximity to the yearly peak, but it does not by itself explain why the stock is staying near that level.
Has Gland Pharma Ltd. made a fresh 52-week high in this streak?
Ans. The latest update confirms that Gland Pharma Ltd. is trading close to its 52-week high, but it should not be read as a claim that a new yearly high was necessarily set today. The article only treats it as a near-high streak.
What is the cumulative move across the Gland Pharma Ltd. 52 Week High Streak?
Ans. The cumulative move reported for the streak is -1.28%. That figure is useful because it captures the full multi-session pattern rather than focusing only on the most recent change in Gland Pharma Ltd. Share Price Today.
Does the data confirm a reason for the repeated near-high trade?
Ans. No. The latest Univest figures confirm the repeated near-high pattern, but they do not establish a company-specific catalyst. Readers should treat the move as a confirmed price pattern, not as a proven event driven by one cause.
Is Gland Pharma Ltd. expensive compared with peers?
Ans. On the latest comparison set, Gland Pharma Ltd. trades above the industry median on P/E and P/B. That places it at a premium to the median peer, although not above every named company in the pharmaceuticals and drugs group.
How does Gland Pharma Ltd. compare on return ratios?
Ans. Gland Pharma Ltd. reports ROE of 10.56% and ROCE of 14.96%. Those levels are broadly in the peer range, with ROCE slightly above the industry median and ROE close to the median for the same industry set.
What should investors monitor next in Gland Pharma Ltd. Stock News?
Ans. Investors can watch whether Gland Pharma Ltd. Share Price continues to stay near the yearly high and whether the valuation premium changes over time. The main near-term focus is the persistence of the streak, not a claimed reason for it.
Why is Gland Pharma Ltd. appearing in stocks at one year high today searches?
Ans. Because Gland Pharma Ltd. 52 Week High Streak keeps the stock close to its 52-week peak for multiple sessions. That naturally puts it in searches tied to stocks at one year high today, stocks in news today and related market update queries.
Track Gland Pharma Ltd. (GLAND) Share Price on Univest
Use Gland Pharma Ltd. (GLAND) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.